Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


	Under the Paperwo	JIK RECUC	Of AUX OF 1950, HO Dela	UISO	a lerimen in lestroin in a conscion i	OF UNCOTTRACTOR OF CONTRACTS IN VALUE CONTRACTS	2010011201120
Substitute for form 1449A/PTO						Complete if Known	
					Application Number	09/619,493	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	July 19, 2000	
					First Named Inventor	N. NASHED et al.	
					Group Art Unit	1616	
(use as many sheets as necessary)				`	Examiner Name	S.N. Qazi	
Sheet	1	of	2	abla	Attorney Docket Number	SCH 1686 C1	

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication of Cited Document Kind Code Name of Patentee or Applicant of Cited Document Examin initials Cite No.1 Number (if known MM-DD-YYYY <u>5 20</u>03 TECH CENTER 1600/2900 FOREIGN PATENT DOCUMENTS ages, Columns, Lines, Foreign Patent Docum Where Relevant
Passages or Relevant ete of Publication of Klod Codes Name of Patentee or Applicant of Cited Document T<sup>4</sup> Cite No.1 Office<sup>3</sup> Number<sup>4</sup> Cited Document Figures Appear Date Considered Examiner Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For sapanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete If Known 09/619,493 **Application Number** INFORMATION DISCLOSURE Filing Date July 19, 2000 STATEMENT BY APPLICANT N. NASHED et al. First Named Inventor 1616 **Group Art Unit** (use as many sheets as necessary) S.N. Qazi **Examiner Name** SCH 1686 C1 Attorney Docket Number Sheet of

<del></del>	<del></del>	NON PATENT LITERATURE DOCUMENTS	. :
Examiner Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т,
	В	E. Freeman et al., Evaluation of a Unique Oral Contraceptive in the Treatment of Premenstrual Dysphoric Disorder, Journal of Women's Heath & Gender-Based Medicine, Vol. 10, No. 6, 2001, pp. 561-569	
	В	E. Freeman et al., A Double-blind Trial of Oral Progesterone, Alprazolam, and Placebo in Treatment of Severe Premenstrual Syndrome, JAMA, Vol. 274, No. 1, July 5, 1995, pp. 51-57	
·	В:	P.M. 'Brien et al., <i>Treatment of Premenstrual Syndrome by Spironolactone</i> , British Journal of Obstetrics and Gynaecology, Vol. 86, February 1979, pp. 142-147	
2093	B	D. Hellberg et al., Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate, Int. J. Gynecol. Obstet., 1991; 34: pp. 243-248	
	В	M. Wang et al., Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study, Acta Obstet Gynecol Scand. 1995: 74: pp. 803-808	
	В	R.B. Burnet et al., <i>Premenstrual Syndrome and Spironolactone</i> , Aust NZ J. Obstet Gynaecol 1991; 31: 4: 366	
	В	K. Aslasksen et al., Spironolactone in the Treatment of Premenstrual Tension: A Double- Blind Study of Spironolactone Versus Bendroflumethiazide and Placebo, Current Therapeutic Research, Vol. 49, No. 1, January 1991, pp. 120-130	
	`		
	1		
•			

Examiner Signature	Sabiha	Ozz	Date Considered	7/6/64
(0.9.1010		<del></del>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF PATENT AND TRADE	F COMMERCE MARK OFFICE	ATTY DOCKET NO. SCH 1686C1			APPLICATION SERIAL NO. 09/619,493		
LIST OF	REFER	REDICES CITED BY AND	JICANT	APPLICANT Norman NASHED					
. 2.0 ( 0. )		SEP 2 5 2007 \$	1	FILING DATE GROUP					
		10	<i>ij</i>	July 19, 2000 1616				1616	
		THE TRADEMINA		U.S. PATENT D	OCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUB CLASS	FILING IF APPRO	
3002	AA-	5,583,129	12/1996	Spona et al.					
2	AB					<u> </u>		<u></u>	
	AC	,					<u> </u>	오	S F
	AD							8	SE T
	AE				<del></del>			<u> </u>	~
	AF								6 _
	AG						<b>\</b>	- 8	200
	AH					ļ		/290	<u> </u>
	Al					<u>.</u>		Ř	
	AJ					<u> </u>	`		
	AK					<u> </u>			
			FO	REIGN PATENT	DOCUMENTS			<u>.                                      </u>	
		DOCUMENT NUMBER	DATE		COUNTRY		YES	TRANSLATIC S	NO NO
	AL	0 640 343 A	3/1/1995		EPO .				
192	AM	43 13 926 A	11/3/1994		GERMANY				
	AN	43 44 462 A	6/29/1995		GERMANY				_
	AO								
	AP								· ·
	AQ								
	AR								
	AS								
		OTHER RE	FERENCES (	(Including Autho	or, Title, Date, Pertinent	t Pages, e	tc.)		<u> </u>
		El-Sherbini, Abbas (CA							
/	ΑT	~							
503	AU	Boekler, H. (CA 78:2446	8, abstract o	f Sportarzt sportr	mad. (1972), 22(9), 233-4	4, 236-7, 1	972.		
	AV	Neuman, Friedmund (CA 118:161077, abstract of Pharm. Ztg. (1992), 137(34), 9-15), 1992.							
	AW	Guenther et al. (CA 113	Guenther et al. (CA 113:218253, abstract of WO 9004397), 1974.						
	AX	L.L. Altshuler et al.: "Pha 1995, pages 233-245	armacologica	l management o	f premenstrual disorder."	HARVAR	D REV. PS	YCHIAT., BD	2 nR. 5,
Examiner		Sabiha	Ø	22		Date Co	nsidered	7/7/	104
*Examiner: In	itial if re	eference is considered, w	hether or not	citation is in con with next comm	formance with MPEP 60 unication to applicant.	9; Draw lin	e through	citation if not in	١

Please type a plus sign (+) inside this box -> +

Sheet

1

of

#9.

SCH 1686 C1

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known **Application Number** 09/619,493 NFORMATION DISCLOSURE Filing Date July 19, 2000 STATEMENT BY APPLICANT N. Nashed et al. First Named Inventor 1616 Group Art Unit (use as many sheets as necessary) Examiner Name S. Qazi

**Attorney Docket Number** 

				U.S. P	ATENT DOCUM	MENTS		
Examiner Initials *	Cite No.	Number	t Document Gnd Code <sup>2</sup> If known)	Name of F	atentee or Applicant ited Document	Date of Publication of Cited Document MM-Dig-YYYY	Pagas, Columns, Lines, Where Relev Passages or Relevant Figures Appear	ent
		( <b>\</b>						
				<u></u>				_
	ļ						<u> </u>	_3
				<u> </u>				
				ļ				_
<u> </u>						\		_
1				ļ			<b>\</b>	_
1			<del>\                                    </del>	<u> </u>			<b>\</b>	
				ļ			<del>                                     </del>	
							<del></del>	_
				ļ			<del>                                     </del>	_
	<b></b>		$\rightarrow$	<u> </u>			ļ <u></u>	
		ļ <u>.</u>	$\rightarrow$	<u> </u>			<del>                                     </del>	_
				↓			<del>                                     </del>	_
	<b>.</b>						<del>                                     </del>	_
	<b>1</b>			1			<del>                                     </del>	
	<u> </u>			1			<del>                                     </del>	
	$\vdash \downarrow$			<u> </u>			<del>                                     </del>	
	$\bot$	<u> </u>		<del>  \                                   </del>				_
	$\overline{}$					···		
				FOREIG	PATENT DOC	UMENTS		
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Foreiç	gn Patent Docu	ment	Name of Patentee	Date of Publication o	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup> K	ind Code <sup>5</sup> (# known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant	۲ <sub>6</sub>
							\\	
							<u> </u>	_
							<u> </u>	
	l	V						_
						\		1
			\			Υ.		1
		11	11.					7
								_
Examiner			11		Date	V		
Signature			11		Cons	sidered	•	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark hee if English language Translation is attached.

TECH CENTER 1600/2900)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number ibstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 3 Sheet 3

Complete if Known						
Application Number	09/619,493					
Filing Date	July 19, 2000					
First Named Inventor	N. Nashed et al.					
Group Art Unit	1616					
Examiner Name	S. Qazi					
Attorney Docket Number	SCH 1686 C1					

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	tnclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
	BL /	Christine P. West, "Inhibition of ovulation with oral progestins-effectiveness in premenstrual syndrome," European Journal of Obstetrics & Gynecology and Reproductive Biology, 34 (1990), pp. 119-128	
	ВМ	~C. Kirkham, MD., et al., "A Randomized, Doubte-Blind, Placebo-Controlled, Cross-Over Trial to Assess the Side Effects of Medroxyprogesterone Acetate In Hormone Replacement Therapy," Obstetrics & Gynecology, Vol. 78, No. 1, July 1991, pp. 93-97	
	BN	L. Dennerstein, et al., "Progesterone and premenstrual syndrome: a double blind crossover trial, "British Medical Journal, Vol. 290, June 1, 1985, pp. 1617-1621	
	во	Peter J. Schmidt, MD., et al., "Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual Syndrome," The New England Journal of Medicine, Vol. 324, No. 17, April 25, 1991, pp. 1174-1179	
SON	\_BP \	John Bancroft et al., "The Impact of Oral Contraceptives on the Experience of Perimenstrual Mood, Clumsiness, Food Craving and Other Symptoms," Journal of Psychosomatic Research, Vol. 37, No. 2, 1993, pp. 195-202	
	Β̈Ω	Cynthia A. Graham, et al., "A Prospective Treatment Study of Premenstrual Symptoms Using a Triphasic Oral Contraceptive," Journal of Psychosomatic Research, Vol. 36, No. 3, 1992, pp. 257-268	
	BR"	Lennart Nilsson et al., "Clinical Studies on Oral Contraceptives-a Randomized, Doubleblind, Crossover Study of 4  Different Preparations (Anoviar® mite, Lyndiol® mite, Ovulen®, and Volidan®)," Acta Obstetrichet Gynecologica Scandinavica," Vol. XLVI, Supplement 8, pp. 2-31	
•	BŠ	Johan Cullberg, "Mood Changes and Menstrual Symptoms with Different Gestagen/Estrogen Combinations," Acta Psychiatrica Scandinavica, Supplementum 236, 1972, pp. 9-86	
	BT .	Sam Silbergeld, Ph.D., MD., et al., "The Menstrual Cycle: A Double-Blind Study of Symptoms, Mood and Behavior, and Blochemical Variables Using Enovid and Placebo," Psychosomatic Medicine, Vol. 33, No. 5 (Sept-Oct 1971), pp. 411-428	
	-BU <sup>1</sup> .	Francis J. Kane, "latrogenic Depression in Women," Phenomenology and Treatment of Depression, Copyright 1977, pp. 69-81	

Examiner SABIHA GAZI	Date Considered	11/13	102
----------------------	--------------------	-------	-----

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

e type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

titute for form 1449A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 3

Complete if Known						
Application Number	09/619,493					
Filing Date	July 19, 2000					
First Named Inventor	N. Nashed et al.					
Group Art Unit	1616					
Examiner Name	S. Qazi					
Attorney Docket Number	SCH 1686 C1					

• .		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		Š
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2	<u> </u>
	BAi	Mabray et al., "Treatment of Common Gynecologic-Endocrinologic Symptoms by Allergy Management Procedures," Obstetrics & Gynecology, Vol. 59, No. 5, May 1982, pp. 560-564		
SON	ВВ	B.P. Appleby, "A Study of Premenstrual Tension in General Practice," British Medical Journal, 2/6/60, pp. 391-393		
	BC <sub>.</sub>	Stuart L. Smith, "Mood and Menstrual Cycle," pp. 19-59		7
	) BD	B. Andersch et al., "Progesterone Treatment of Premenstrual Tension-A Double Blind Study," Journal of Psychosomatic Research, Vol. 29, No. 5, 1985, pp. 489-493		
	BE \	Michael A. Richter, M.D., et al., "Progesterone Treatment of Premenstrual Syndrome," Current Therapeutic Research, Vol. 36, No. 5, Nov. 1984, pp. 840-850		
•	BF	Gwyneth A Sampson, "Premenstrual Syndrome: A Double-Blind Controlled Trial of Progesterone and Placebo."  Brit. J. Psychiat. (1979), 135, 209-215		
CDD	BG	Sarah Maddocks, et al., "A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome," Am J Obstet Gynecol, March 1986, pp. 573-581		
300 2	вн	Ellen Freeman, et al., "Ineffectiveness of Progesterone Suppository Treatment for Premenstrual Syndrome,"  JAMA, Vol. 264, No. 3, July 18, 1990, pp. 349-353		
	Bi	. Lorraine Dennerstein, et al., "Treatment of Premenstrual Syndrome a Double-blind Trial of Dydrogesterone," . Journal of Affective Disorders, 11 (1986), pp-199-205		]
	BJ	Gwyneth A. Sampson, et al., "Premenstrual Syndrome A Double-blind Cross-over Study of Treatment with Dydrogesterone and Placebo," British Journal of Psychiatry, 153 (1988), pp. 232-235		
	ВК	Pekka Ylostalo, et al., "Bromocriptine and Norethisterone in the Treatment of Premenstrual Syndrome," Obstetrics & Gynecology, Vol. 58, No. 3, March, 1982, pp. 292-298		]

			7	1 7
Examiner	Capula	0-1-	Date	1 11/15/10/
Signature	JABIHA	$\forall HZI$	Considered	11/15/02
(3.3.12.12.3				<u></u>

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.